The funding, which was co-led by Pfizer Ventures and EcoR1 Capital, will help drive ReCode's therapy programs for primary ciliary dyskinesia and cystic fibrosis into human clinical studies.
North Texas’ growing venture capital community was on full display Thursday at Old Parkland, as an estimated 450 company founders, investors and other community leaders gathered for the sixth annual Venture Dallas conference....
North Texas’ growing venture capital community was on full display Thursday at Old Parkland, as an estimated 450 company founders, investors and other community leaders gathered for the sixth annual Venture Dallas conference....